A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT03337724
Completed
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Memorial Regional Hospital, Hollywood, Florida +3 locations
Conditions: Breast Cancer
Register for Updates
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
NCT03326102
Completed
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Boca Raton Regional Hospital (BRRH), Boca Raton, Florida +1 locations
Conditions: Recurrent or Metastatic Breast Cancer
Register for Updates
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
NCT01953926
Terminated
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida +1 locations
Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Register for Updates
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
NCT03840902
Terminated
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Lynn Cancer Institute Center, Boca Raton, Florida +2 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117
Active Not Recruiting
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: AdventHealth Orlando, Orlando, Florida +1 locations
Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Register for Updates
Study of ORIC-101 in Combination With Anticancer Therapy
NCT03928314
Terminated
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Florida Cancer Specialists & Research Institute, Lake Mary, Florida +1 locations
Conditions: Solid Tumor
Register for Updates
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
NCT02887248
Terminated
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or cisplatin-incurable advanced urothelial carcinoma (UC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Florida Cancer Specialists - South, Fort Myers, Florida +2 locations
Conditions: Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
Register for Updates
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
NCT03189914
Completed
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Rexahn Site, Weeki Wachee, Florida
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
NCT02599324
Completed
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Duplicate_Cancer Specialist of North Florida (CSNF) ( R ) /ID# 1128-1093, Jacksonville, Florida
Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Register for Updates
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
NCT02826161
Terminated
This is an international, multi-center, prospective, randomized, open-label Phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with advanced non-squamous non-small cell lung cancer who have disease progression following systemic treatment with a platinum-based combination regimen in the metastatic setting, who have received treatment with an immune checkpoint inhibitor if a candidate, additional appro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Not set, Aventura, Florida
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731
Completed
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Florida Cancer Specialists & Research Institute, Fort Myers, Florida +8 locations
Conditions: Carcinoma, Pancreatic Ductal
Register for Updates
Trial of NanoPac Intratumoral Injection in Lung Cancer
NCT04314895
Completed
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: University of Florida Health, Gainesville, Florida
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Register for Updates